ClinicalTrials.gg
CompletedNCT00510406SATURNUpdated Aug 20, 2014

A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH

A Phase 2 interventional study of tamsulosin hydrochloride and solifenacin succinate in Lower Urinary Tract Symptoms and Prostatic Hyperplasia, sponsored by Astellas Pharma Inc. Completed at 98 sites in 16 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2014-08-20.

Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
919
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing tamsulosin in Lower Urinary Tract Symptoms — 5 open to participants now, 5 under way, none of them phase 3. Tamsulosin · Lower Urinary Tract Symptoms.

Enrollment
4th of 22
919 · median 136
Started
2007
with 2 others
Phase 2
4 of 22
none open now
Registered
2nd of 22
by date
Lead sponsor
2 of 22
Astellas Pharma Inc

Among the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms, this one is the 4th largest by enrollment, is one of 3 that started in 2007, is one of 4 in phase 2, and was the 2nd registered.

Lower Urinary Tract Symptoms

417 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.

Browse Lower Urinary Tract Symptoms studies →

Open to participants now

5 of the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Lower Urinary Tract Symptoms studies recruiting now, 39 (66%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing tamsulosin in Lower Urinary Tract Symptoms, or all of them as a file.
02

Study summary

The study will examine the efficacy,safety and tolerability of combination therapy of tamsulosin and solifenacin compared to placebo and monotherapy of tamsulosin and solifenacin in the treatment of males with LUTS associated with BPH.

Read the detailed description

Placebo Solifenacin succinate Tamsulosin hydrochloride Tamsulosin hydrochloride + solifenacin succinate

The primary comparison will be the combination treatment with tamsulosin hydrochloride monotherapy.

Other comparisons will be:

Placebo and combination treatment. Solifenacin monotherapy and combination treatment

03

Conditions studied

  • Lower Urinary Tract Symptoms
  • Prostatic Hyperplasia

Keywords

  • Lower Urinary Tract Symptoms
  • Treatment
  • Solifenacin succinate
  • Tamsulosin hydrochloride
  • Prostatic Hyperplasia
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male patients with LUTS associated with BPH diagnosed > 3 months
  • IPSS score > 13
  • voiding and storage symptoms
  • maximum flow rate of > 4 mL/s and \< 15 mL/s

Exclusion criteria

Exclusion Criteria:

  • post void residual volume > 200 mL
  • symptomatic urinary tract infection
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
919 participants (actual)

Study arms

  • Placebo comparator
    A

    Drug: Placebo

  • Active comparator
    B

    Drug: solifenacin succinate

  • Active comparator
    C

    Drug: solifenacin succinate

  • Active comparator
    D

    Drug: solifenacin succinate

  • Active comparator
    E

    Drug: tamsulosin hydrochloride

  • Active comparator
    F

    Drug: tamsulosin hydrochloride · Drug: solifenacin succinate

  • Active comparator
    G

    Drug: tamsulosin hydrochloride · Drug: solifenacin succinate

  • Active comparator
    H

    Drug: tamsulosin hydrochloride · Drug: solifenacin succinate

Interventions

06

What researchers measure

Primary outcomes

  1. Assess whether the combination of solifenacin succinate and tamsulosin hydrochloride provides improved efficacy compared to tamsulosin hydrochloride alone in males with LUTS associated with BPH

    Time frame: 12 weeks

Secondary outcomes

  1. Assess efficacy, safety, tolerability and PK of the combination of solifenacin succinate and tamsulosin hydrochloride

    Time frame: 12 weeks

07

Study locations

98 sites
  • Linz, North-West, Austria
  • Graz, Styria, Austria
  • Wien, Vienna, Austria
  • Ostrava, Czech Republic
  • Plzen, Czech Republic
  • Prague, Czech Republic
  • Usti nad Labem, Czech Republic
  • Aalborg, Denmark
  • Frederiksberg, Denmark
  • Roskilde, Denmark
  • Skejby, Denmark
  • Helsinki, Finland
  • Kuopio, Finland
  • Lahti, Finland
  • Oulu, Finland
  • Tampere, Finland
  • Colmar, France
  • Cote de Nacre, France
  • Creteil, France
  • Marseille, France
  • Montlucon, France
  • Mulhouse, France
  • Nimes, France
  • Paris, France
  • Ploemer, France
  • Bad Segeberg, Germany
  • Bamberg, Germany
  • Bautzen, Germany
  • Dresden, Germany
  • Ganderkessee, Germany
  • Hagenow, Germany
  • Halle/Saale, Germany
  • Hamburg, Germany
  • Henningsdorf, Germany
  • Hettstedt, Germany
  • Koblenz, Germany
  • Leipzig, Germany
  • Lutherstadt Eisleben, Germany
  • Munchen, Germany
  • Münster, Germany
  • Neustadt i. Sachsen, Germany
  • Trier, Germany
  • Uetersen, Germany
  • Budapest, Hungary
  • Eger, Hungary
  • Miskolc, Hungary
  • Nyiregyháza, Hungary
  • Sopron, Hungary
  • Szeged, Hungary
  • Szekszárd, Hungary
  • Tatabánya, Hungary
  • Sneek, Friesland, Netherlands
  • Nijmegen, Gelderland, Netherlands
  • Maastricht, Limburg, Netherlands
  • S'Hertogenbosch, Noord-brabant, Netherlands
  • Tilburg, Noord-brabant, Netherlands
  • Amsterdam, Noord-Holland, Netherlands
  • Apeldoorn, Overijssel, Netherlands
  • Deventer, Overijssel, Netherlands
  • Utrecht, Netherlands
  • Fredrikstad, Norway
  • Oslo, Norway
  • Tonsberg, Norway
  • Bialystok, Poland
  • Bydgoszcz, Poland
  • Cracow, Poland
  • Katowice, Poland
  • Lublin, Poland
  • Lódz, Poland
  • Pulawy, Poland
  • Szczecin, Poland
  • Warszawa, Poland
  • Amadora-Sintra, Portugal
  • Carmo, Portugal
  • Coimbra (Covões), Portugal
  • Orta EPE, Portugal
  • Pulido Valente, Portugal
  • Santa Luzia, Portugal
  • Tomar, Portugal
  • Moscow, Russian Federation
  • St. Petersburg, Russian Federation
  • Nitra, Slovakia
  • Trencin, Slovakia
  • Zilina, Slovakia
  • Barcelona, Spain
  • La Coruna, Spain
  • Madrid, Spain
  • Pontevedra, Spain
  • Sevilla, Spain
  • Kungälv, Sweden
  • Stockholm, Sweden
  • Sundsvall, Sweden
  • Uddevalla, Sweden
  • Upsala, Sweden
  • Reading, Berkshire, United Kingdom
  • Chorley, Lancashire, United Kingdom
  • Cardiff, Wales, United Kingdom
  • Swansea, Wales, United Kingdom
08

References and documents

Publications

  • Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, Garcia-Hernandez A, Klaver M, Traudtner K, Oelke M. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013 Sep;64(3):398-407. doi: 10.1016/j.eururo.2013.03.031. Epub 2013 Mar 19. PubMed 23537687 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2007
First posted
Aug 2, 2007
Start
Jan 2007
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Last update
Aug 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00510406
Responsible party
Sponsor
First posted
Aug 2, 2007
Start date
Jan 2007
Primary completion
Sep 2007
Completion
Sep 2007
Last update
Aug 20, 2014

Study contacts

Central Contact
study director · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tamsulosin · Solifenacin

Start the discussion